Cosmos Health Q3 Revenue Rises 38% to $17.1 Million

Reuters

2025/11/17

<a href="https://laohu8.com/S/COSM">Cosmos Health</a> Q3 Revenue Rises 38% to $17.1 Million

Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584062154"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584062154\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584062154?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 22:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584062154","market":"us","top_or_hot":-1,"title":"Cosmos Health Q3 Revenue Rises 38% to $17.1 Million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COSM\">Cosmos Health</a> Q3 Revenue Rises 38% to $17.1 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cosmos Health Q3 Revenue Rises 38% to $17.1 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCosmos Health Q3 Revenue Rises 38% to $17.1 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-17 22:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/COSM\">Cosmos Health</a> Q3 Revenue Rises 38% to $17.1 Million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"COSM","symbol_name":"COSMOS HEALTH INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL77V60m:1","article_id":"2584062154","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584062154","pubTimestamp":1763388988,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income  per share improved to $ from $ in Q3 2024, and adjusted EPS improved to $ from $. For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $ last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing fa","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"COSM":"COSMOS HEALTH INC","BK4175":"保健护理产品经销商"},"translate_title":"Cosmos Health第三季度收入增长38%至1710万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"COSM":0.9},"content_text":"Cosmos Health Q3 Revenue Rises 38% to $17.1 Million\n    \n\n        Cosmos Health Inc. reported record financial results for the third quarter of 2025, with revenue reaching $17.1 million, a 38% increase from $12.4 million in the same period of 2024. Gross profit rose 116% to $2.6 million. Adjusted EBITDA increased by 74%. Net income (loss) per share improved to $(0.17) from $(0.45) in Q3 2024, and adjusted EPS improved to $(0.02) from $(0.34). For the nine months ended September 30, 2025, revenue was $45.6 million, up 13% from $40.2 million in the prior-year period, with adjusted EPS turning positive to $0.02 from $(0.53) last year. The company ended the quarter with a cash position of $4.6 million, up from $0.7 million. Business developments included record performance across all core segments, continued growth in contract manufacturing at Cana Laboratories, strong sales through Decahedron in the UK, increased volumes in the CosmoFarm distribution business, and international expansion of proprietary brands such as Sky Premium Life. Cosmos Health also secured a $300 million financing facility to support its digital assets portfolio and long-term strategy.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cosmos Health Inc. published the original content used to generate this news brief on November 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}